Ignacio Melero
Professor of Immunology at the University of Navarra, CIMA researcher and co-director of the Department of Immunology and Immunotherapy at the Clínica Universidad de Navarra.
It is a work of exceptional quality and clearly a game changer in medical practice.
It applies to paediatric patients. Evidence was previously available in adult patients and in children after chemotherapy failure. Here the bispecific antibody is used in the first line of treatment with a very good safety and efficacy profile, although only evidence for high-risk patients with KMT2A gene rearrangement.
There are still a certain percentage of patients who relapse and the reasons for relapse should be studied in depth, considering first-line treatment combinations for this subgroup of patients.
The follow-up period with detection of minimal residual disease is very significant. As time goes on, the patients in this study who remain in follow-up will allow further data to be collected.
It is a treatment that in principle corresponds to patients with the KMT2A rearrangement, which represents 2-4% of paediatric patients.